Charenton Le Pont, France

Lambros Tselikas

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Institut Gustave Roussy, Université Paris-Saclay. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Lambros Tselikas

Introduction

Lambros Tselikas is a notable inventor based in Charenton Le Pont, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injectable formulations. His work focuses on enhancing the delivery of therapeutic agents through innovative emulsion technologies.

Latest Patents

One of Tselikas's key inventions is a patent for "Injectable water-in-oil emulsions and uses thereof." This patent describes a water-in-oil emulsion that consists of a continuous oil phase and an aqueous phase dispersed in the form of drops. The aqueous phase includes polyester-based nanoparticles and at least one therapeutic agent, which can improve the efficacy of drug delivery.

Career Highlights

Throughout his career, Lambros Tselikas has worked with prestigious institutions such as the Institut Gustave Roussy and the Centre National de la Recherche Scientifique. His experience in these organizations has allowed him to contribute to cutting-edge research and development in the medical field.

Collaborations

Tselikas has collaborated with several professionals in his field, including Frédéric Deschamps and Thierry De Baere. These collaborations have further enriched his research and innovation efforts.

Conclusion

Lambros Tselikas is a prominent figure in the realm of pharmaceutical inventions, with a focus on improving drug delivery systems. His innovative work continues to impact the medical community positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…